Dry Age-Related Macular Degeneration | DecisionBase | 2014
What Do Physicians and U.S. Payers Expect from the First-to-Market Therapies Targeting Geographic Atrophy?
Geographic atrophy (GA) is the advanced dry form of age-related macular degeneration (AMD). Although vision loss caused by GA can be gradual, the disease nonetheless has a steadily increasing negative effect on the lives of affected individuals. No therapies are currently approved for the treatment of GA, and with more than 1.5 million prevalent GA cases across the G7 markets, significant opportunity exists for first-to-market agents.
Related Market Assessment Reports
Report
Dry and Wet Age-Related Macular Degeneration – Current Treatment – Treatment Algorithms: Claims Data Analysis – Wet Age-Related Macular Degeneration (US)
The U.S. market for wet age-related macular degeneration (wet AMD) is in transition as newer therapies, including biosimilars, increasingly enter the treatment algorithm. While intravitreal options…
Report
Dry and Wet Age-Related Macular Degeneration – Landscape & Forecast – Disease Landscape & Forecast (G7)
Age-related macular degeneration (AMD) is a late-onset retinal disease that diminishes central visual acuity due to photoreceptor degeneration in the macula, leading to vision impairment and…
Report
Dry and Wet Age-Related Macular Degeneration – Unmet Need – Unmet Need – Wet Age-Related Macular Degeneration (US/EU)
Wet AMD (age-related macular degeneration) is a leading cause of vision loss among older adults, with significant implications on patient’s independence and quality of life. The treatment…
Report
Dry and Wet Age-Related Macular Degeneration | Treatment Algorithms: Claims Data Analysis | Wet Age-Related Macular Degeneration | US | 2025
With the introduction of extended-duration therapies like Roche’s Vabysmo and Regeneron’s Eylea HD, the U.S. market for wet age-related macular degeneration (AMD) is undergoing significant changes…
